|
|
News Breaks
|
November 24, 2009
|
| 06:39 EDT |  | BAYRY |
| theflyonthewall.com: | Bayer CropScience signs agreement with GVK Biosciences | | Bayer CropScience (BAYRY) and GVK Biosciences Private Limited, Hyderabad, India, have entered into a research cooperation in the area of early discovery chemistry. The objective is to speed up the search for promising active ingredients for innovative crop protection products. Under the agreement, Bayer CropScience will integrate GVK BIO capacities in the early part of its Discovery chemistry process. :theflyonthewall.com |
|
|
News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 16:09 EDT | | BAYRY |
| theflyonthewall.com: | Watson Pharmaceuticals confirms Beyaz patent challenge | | Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is a generic version of Bayer HealthCare Pharmaceuticals' (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception. :theflyonthewall.com |
| | 15:30 EDT |  | BAYRY |
| | 14:11 EDT | | BAYRY |
| | 11:58 EDT |  | BAYRY |
|
|
January 30, 2012
|
| 07:29 EDT | | BAYRY |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information